Discrimination and reclassification statistics for the calculated values of the various risk scores that were studied, in both populations of post-MI subjects and for IMACE and DAPT-S in a secondary validation of non-MI poststent subjects
| Sex | Model | Derivation c-statistics | Validation c-statistics | NRI index for IMACE vs the indicated score |
| Female | n=1342 | n=576 | ||
| IMACE | 0.675 | 0.734 | – | |
| e-IMACE | 0.717 | 0.717 | N/C | |
| IMRS | 0.652 | 0.690 | 0.478 (P<0.001) | |
| GRACE | 0.603 | 0.632 | 0.282 (P<0.001) | |
| DAPT-S | 0.546 | 0.574 | N/C | |
| DAPT-S no age | 0.606 | 0.649 | 0.205 (P<0.001) | |
| Male | n=3047 | n=1290 | ||
| IMACE | 0.715 | 0.672 | – | |
| e-IMACE | 0.734 | 0.667 | N/C | |
| IMRS | 0.633 | 0.629 | 0.250 (P<0.001) | |
| GRACE | 0.649 | 0.670 | 0.127 (P<0.001) | |
| DAPT-S | 0.581 | 0.551 | N/C | |
| DAPT-S, no age | 0.661 | 0.628 | 0.157 (P<0.001) | |
| Second validation population of non-MI poststent subjects (women, n=1779; men, n=4977) | ||||
| Female | IMACE | NA | 0.635 | – |
| DAPT-S | NA | 0.510 | N/C | |
| DAPT-S, no age | NA | 0.581 | 0.044 (P<0.001) | |
| Male | IMACE | NA | 0.635 | – |
| DAPT-S | NA | 0.553 | N/C | |
| DAPT-S, no age | NA | 0.619 | 0.026 (P<0.001) | |
NRI index was calculated for validation subjects.
DAPT, dual antiplatelet therapy; DAPT-S, DAPT Study; e-IMACE, enhanced IMACE; GRACE, Global Registry of Acute Coronary Events; IMACE, Intermountain Major Adverse Cardiovascular Events; IMRS, Intermountain Mortality Risk Scores; MI, myocardial infarction; NA, not applicable; N/C, not calculated; NRI, net reclassification improvement.